SCHEMBL24329616

SCHEMBL24329616

O=C(c1ccc(CBr)c(F)c1)C1CC1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HSD11B1 P28845 3/20 0.43
▸ GRM1 Q13255 5/20 0.42
▸ FFAR4 Q5NUL3 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ HTR1F P30939 1/20 0.38
▸ HTR2A P28223 1/20 0.38
▸ HTR2C P28335 1/20 0.38
▸ HTR7 P34969 1/20 0.38
▸ HTR6 P50406 1/20 0.38
▸ MGLL Q99685 1/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ CYP2D6 P10635 1/20 0.37
▸ KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29555311 1.00 HSD11B1 (0.43) HSD11B1GRM1FFAR4ALDH1A1LMNA
SCHEMBL20202558 0.85 GRM1 (0.52) HSD11B1GRM1NPC1RAB9AMEN1
SCHEMBL18285763 0.81 HSD11B1 (0.41) HSD11B1GRM1FFAR4ALDH1A1LMNA
SCHEMBL21448795 0.79 HSD11B1 (0.60) HSD11B1ALDH1A1LMNAHSD17B10HTR1F
SCHEMBL4944008 0.78 HSD11B1 (0.46) HSD11B1ALDH1A1LMNAHSD17B10HTR1F
SCHEMBL973055 0.78 EPHX2 (0.50) ALDH1A1LMNAHSD17B10RAB9A
SCHEMBL17253039 0.76 SNCA (0.47) HSD11B1ALDH1A1LMNAHSD17B10MGLL
SCHEMBL20300366 0.76 PARP1 (0.44) HSD17B10HTR2CHTR7HTR6MEN1
SCHEMBL14870737 0.75 HDAC1 (0.54) HSD11B1GRM1ALDH1A1LMNAHSD17B10
SCHEMBL14866142 0.74 MGLL (0.45) HSD11B1GRM1ALDH1A1LMNAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250263402-A1 BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO., LTD. (CN) 2025-08-21 — — US disclosed
EP-4227299-A1 BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. (CN) 2023-08-16 — — EP disclosed
EP-4227299-A1 BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. (CN) 2023-08-16 — — EP disclosed
WO-2022078152-A1 BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF 杭州中美华东制药有限公司 2022-04-21 — — WO disclosed
WO-2022078152-A1 BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF 杭州中美华东制药有限公司 2022-04-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250263402-A1 BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF GLP1R, GIPR, GCGR HSD11B1 2191/4885GRM1 173/4885FFAR4 65/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback